Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media.
Antimicrobial treatment failures in children with acute otitis media and concomitant viral respiratory tract infection prompted us to study the effects of influenza A virus infection on middle ear antimicrobial drug penetration. Using a chinchilla model of Streptococcus pneumoniae we compared middle ear elimination rates in 4 groups of chinchillas: (1) control, (2) influenza A virus inoculation alone intranasally, (3) both influenza A and S. pneumoniae inoculation directly into the middle ear, and (4) S. pneumoniae inoculation alone into the middle ear. After infection was established, a solution containing amoxicillin, sulfamethoxazole, and trimethoprim was instilled into the middle ear and removed 4 hours later. The rate constant of elimination and half-life were calculated from measured drug concentrations initially and at 4 hours. S. pneumoniae infection alone significantly shortened the middle ear elimination half-life compared with the control group: amoxicillin, 2.65 +/- 0.73 vs. 6.63 +/- 2.55 hr; sulfamethoxazole, 1.75 +/- 0.28 vs. 2.74 +/- 0.6 hr; and trimethoprim, 1.06 +/- 0.14 vs. 1.56 +/- 0.34 hr (n = 16 ears, p values all < 0.01). The combined influenza virus and S. pneumoniae infection significantly lengthened the half-life compared with the S. pneumoniae infection alone: amoxicillin, 5.65 +/- 6.44 vs. 2.65 +/- 0.73 hr; sulfamethoxazole, 2.5 +/- 0.85 vs. 1.75 +/- 0.28 hr; and trimethoprim, 1.26 +/- 0.42 vs. 1.06 +/- 0.14 hr (n = 16 ears, p values all < 0.01). Influenza virus produced the longest half-lives for all 3 antimicrobials: amoxicillin 25.52 +/- 14.96 hr; sulfamethoxazole, 5.46 +/- 0.87 hr; and trimethoprim, 2.57 +/- 0.75 hr.(ABSTRACT TRUNCATED AT 250 WORDS)
Jossart
G H
GH
Otitis Media Research Center, School of Medicine, University of Minnesota, Minneapolis 55455.
Canafax
D M
DM
Erdmann
G R
GR
Lovdahl
M J
MJ
Russlie
H Q
HQ
Juhn
S K
SK
Giebink
G S
GS
D000658:Amoxicillin / Q000493:pharmacokinetics; D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D002682:Chinchilla; D006207:Half-Life; D009980:Influenza A virus; D009092:Mucous Membrane / Q000378:metabolism; D009976:Orthomyxoviridae Infections / Q000378:metabolism* / Q000821:virology; D010033:Otitis Media / Q000378:metabolism* / Q000382:microbiology / Q000821:virology; D011008:Pneumococcal Infections / Q000378:metabolism*; D011817:Rabbits; D013420:Sulfamethoxazole / Q000493:pharmacokinetics; D014295:Trimethoprim / Q000493:pharmacokinetics
D000890:Anti-Infective Agents; D000658:Amoxicillin; D014295:Trimethoprim; D013420:Sulfamethoxazole